Welcome to our dedicated page for Apyx Medical Corporation news (Ticker: APYX), a resource for investors and traders seeking the latest updates and insights on Apyx Medical Corporation stock.
About Apyx Medical Corporation
Apyx Medical Corporation (NASDAQ: APYX) is an advanced energy technology company specializing in the development, manufacturing, and marketing of innovative medical devices for the cosmetic and surgical markets worldwide. With a strong focus on leveraging proprietary technologies, Apyx delivers cutting-edge solutions that elevate surgical precision and aesthetic outcomes.
The company operates through two primary business segments: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment is centered around its patented Helium Plasma Platform Technology, which is marketed under the Renuvion brand name in the cosmetic surgery market and as J-Plasma in the hospital surgical market. These technologies enable surgeons to achieve unparalleled precision in cutting, coagulation, and ablation of soft tissue while minimizing unintended tissue trauma. The Renuvion system, in particular, empowers plastic surgeons, facial plastic surgeons, and cosmetic physicians to deliver controlled heat to tissue, enhancing patient outcomes in body contouring and other aesthetic procedures.
In addition to its proprietary technologies, Apyx's OEM segment designs, develops, and manufactures electrosurgical generators and related accessories for other medical device manufacturers. This segment leverages the company's decades of expertise in advanced waveforms, allowing it to establish strategic partnerships and diversify its revenue streams.
Industry Position and Market Impact
Apyx Medical Corporation operates at the intersection of the medical device and cosmetic surgery industries, addressing a growing demand for minimally invasive and precise surgical solutions. The company's Renuvion and J-Plasma technologies are supported by extensive clinical validation, with over 90 published clinical documents attesting to their efficacy and safety. This robust evidence base enhances the company's credibility and fosters trust among surgeons and patients alike.
By focusing on innovation and quality, Apyx distinguishes itself in a competitive landscape that includes other advanced energy technology providers. Its ability to address both cosmetic and surgical applications positions it uniquely within its market segments, catering to a diverse customer base that spans hospitals, surgery centers, and private practices.
Commitment to Innovation and Quality
As a company formerly known as Bovie Medical Corporation, Apyx has a legacy of expertise in energy-based medical technologies. Its ongoing commitment to research and development ensures that it remains at the forefront of surgical innovation. By integrating advanced technology with user-centric design, Apyx continues to enhance the capabilities of surgeons and improve patient outcomes.
Conclusion
Apyx Medical Corporation exemplifies the convergence of innovation, precision, and clinical excellence in the medical device industry. Through its proprietary Helium Plasma Platform Technology and strategic OEM partnerships, the company addresses critical needs in both surgical and cosmetic markets. With a focus on delivering transformative solutions and maintaining rigorous quality standards, Apyx is well-positioned to drive meaningful advancements in the field of energy-based medical devices.
Apyx Medical Corporation (NASDAQ:APYX) announced that it will release its financial results for Q1 of fiscal year 2023 before the market opens on May 11th. A conference call will follow at 8:00 a.m. Eastern Time on the same day, allowing for a discussion of the results and a Q&A session. Interested callers can join by dialing 877-407-8289 (or 201-689-8341 internationally) with access code 13737575. A live webcast will also be available through the Company’s Investor Relations section. This financial update is anticipated to provide insights into Apyx Medical's performance in the advanced energy technology market, including its innovative products Renuvion and J-Plasma, which are designed for cosmetic and hospital surgical applications.
Apyx Medical Corporation (NASDAQ:APYX) reported its Q4 and full year 2022 results, revealing a 25% decline in total revenue to $12.6 million for Q4, and a 8% decrease for the year to $44.5 million. Advanced Energy revenue dropped 30% year-over-year to $10.5 million in Q4, while OEM revenue increased 15%. The company experienced a net loss of $6.0 million for Q4, worsening from $2.0 million a year earlier, and a loss of $23.2 million for 2022. Looking ahead, Apyx anticipates 2023 revenue between $58.0 million and $61.0 million, indicating a potential growth of 30% to 37% year-over-year. Key developments included the launch of a new marketing campaign and a secured $35 million credit facility.
Apyx Medical Corporation (NASDAQ:APYX) has received 510(k) clearance from the U.S. FDA for its Renuvion APR Handpiece. This device is approved for delivering radiofrequency energy and/or helium plasma for soft tissue coagulation and contraction, specifically subcutaneous tissue. CEO Charlie Goodwin emphasized this clearance underscores Renuvion's safety and effectiveness. Apyx is currently seeking an additional indication for use following liposuction, which remains under FDA review. The company specializes in advanced energy technology, aiming to elevate patient outcomes in cosmetic and surgical markets.
Apyx Medical Corporation has secured a new five-year credit facility worth up to
Apyx Medical Corporation (NASDAQ: APYX) announced it will release its financial results for Q4 and fiscal year 2022 before the market opens on March 16th. Management will hold a conference call at 8:00 a.m. ET that same day to discuss these results and answer questions. Interested parties can access the call by dialing 877-407-8289 (international: 201-689-8341) using access code 13736530. The call will also be available via a live webcast. Apyx Medical specializes in advanced energy technology, particularly in helium plasma products marketed as Renuvion and J-Plasma for cosmetic and surgical applications.
Apyx Medical Corporation (NASDAQ:APYX) announced that its Renuvion neck laxity procedure will be featured on 'The Balancing Act' talk show on Lifetime on February 13, 2023, at 7:30 am ET/PT. The segment will showcase a minimally invasive neck procedure performed by Dr. Charles J. Galanis, highlighting its effectiveness in reducing sagging skin. Renuvion is the only FDA-cleared product for addressing neck and chin skin laxity, offering patients minimal downtime and cost-effectiveness. The segment will also re-run on February 21, 2023, with additional broadcasts throughout the year.
Apyx Medical Corporation (NASDAQ:APYX) has submitted a 510(k) premarket notification to the U.S. FDA for its Renuvion APR Handpiece, aiming to expand its use for coagulating subcutaneous soft tissues after liposuction. Supported by a clinical study and extensive evidence, the submission indicates that no new risks are associated with Renuvion when used post-liposuction. CEO Charlie Goodwin expressed optimism about receiving the FDA clearance, which may alleviate existing limitations outlined in the Medical Device Safety Communication.
FAQ
What is the current stock price of Apyx Medical Corporation (APYX)?
What is the market cap of Apyx Medical Corporation (APYX)?
What does Apyx Medical Corporation specialize in?
What are Apyx's primary product offerings?
How does Apyx generate revenue?
What markets does Apyx serve?
What differentiates Apyx from competitors?
What is the Renuvion system used for?
What is the J-Plasma system designed for?
What is Apyx's approach to innovation?
Does Apyx have strategic partnerships?
What is Apyx's legacy in the medical device industry?
